Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review
暂无分享,去创建一个
[1] S. Hautaniemi,et al. Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. , 2011, Oncology reports.
[2] J. Pagel,et al. Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium , 2010, Leukemia & lymphoma.
[3] Angela G. Fleischman,et al. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. , 2013, Cancer discovery.
[4] Steven A. Rosenberg,et al. Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.
[5] P. Möller,et al. STAT6 activity is regulated by SOCS-1 and modulates BCL-XL expression in primary mediastinal B-Cell lymphoma , 2008, Leukemia.
[6] L. Staudt,et al. A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator’s Choice in Relapsed/Refractory DLBCL , 2014 .
[7] R. Houot,et al. A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma , 2013, Clinical Cancer Research.
[8] J. Leonard,et al. Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. , 2013, Hematology. American Society of Hematology. Education Program.
[9] L. Staudt,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[10] Alexandra G. Smith,et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network , 2011, British Journal of Cancer.
[11] R. Aguiar,et al. B-aggressive Lymphoma Family Proteins Have Unique Domains That Modulate Transcription and Exhibit Poly(ADP-ribose) Polymerase Activity* , 2005, Journal of Biological Chemistry.
[12] Ryan D. Morin,et al. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma. , 2015, Blood.
[13] A. Mackensen,et al. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy , 2005, Cancer Immunology, Immunotherapy.
[14] G. Cohen,et al. ABT‐199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets , 2013, British journal of haematology.
[15] J. Delabie,et al. Lymphocyte predominance Hodgkin disease is characterized by recurrent genomic imbalances. , 2001, Blood.
[16] M. Shipp,et al. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies , 2013, Clinical Cancer Research.
[17] L. Kats,et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo , 2014, Leukemia.
[18] R. Weichselbaum,et al. STAT1 Pathway Mediates Amplification of Metastatic Potential and Resistance to Therapy , 2009, PloS one.
[19] H. Handa,et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.
[20] Ash A. Alizadeh,et al. Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell-like and activated B-cell-like diffuse large-cell lymphomas. , 2005, Blood.
[21] C. D. Andersson,et al. Discovery of ligands for ADP-ribosyltransferases via docking-based virtual screening. , 2012, Journal of medicinal chemistry.
[22] M. Boothby,et al. Selective potentiation of Stat-dependent gene expression by collaborator of Stat6 (CoaSt6), a transcriptional cofactor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[23] A. LaCasce,et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma , 2013, Haematologica.
[24] M. Nussenzweig,et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. , 2012, Blood.
[25] W. Choi,et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. , 2013, Blood.
[26] S. Monti,et al. FAS Death Domain Deletions and Cellular FADD-like Interleukin 1β Converting Enzyme Inhibitory Protein (Long) Overexpression: Alternative Mechanisms for Deregulating the Extrinsic Apoptotic Pathway in Diffuse Large B-Cell Lymphoma Subtypes , 2006, Clinical Cancer Research.
[27] W. Choi,et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. , 2012, Blood.
[28] M. Holtzman,et al. Modification of the Stat1 SH2 Domain Broadly Improves Interferon Efficacy in Proportion to p300/CREB-binding Protein Coactivator Recruitment*♦ , 2005, Journal of Biological Chemistry.
[29] L. Cascione,et al. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs , 2015, Clinical Cancer Research.
[30] R. Tibshirani,et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. , 2000, Blood.
[31] J. Monroe. ITAM-mediated tonic signalling through pre-BCR and BCR complexes , 2006, Nature Reviews Immunology.
[32] L. Staudt,et al. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy , 2011, Haematologica.
[33] T. Barth,et al. [Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line]. , 2004, Verhandlungen der Deutschen Gesellschaft fur Pathologie.
[34] Jordi Mestres,et al. Identification of pim kinases as novel targets for PJ34 with confounding effects in PARP biology. , 2012, ACS chemical biology.
[35] R. Donnelly,et al. Resistance to IFN-α–Induced Apoptosis Is Linked to a Loss of STAT2 , 2010, Molecular Cancer Research.
[36] G. Lenz,et al. I{kappa}B-{zeta} controls the constitutive NF-{kappa}B target gene network and survival of ABC DLBCL , 2013 .
[37] B. Turk,et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.
[38] R. Mirimanoff,et al. Clinical implications of the p53 tumor-suppressor gene. , 1994, The New England journal of medicine.
[39] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[40] T. Molina,et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. , 2009, Blood.
[41] W. Wilson,et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] O. McGuinness,et al. Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family , 2011, Proceedings of the National Academy of Sciences.
[43] Christian Steidl,et al. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. , 2011, Blood.
[44] R. Gascoyne,et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.
[45] W. Wilson,et al. Diffuse large B cell lymphoma: molecular targeted therapy , 2012, International Journal of Hematology.
[46] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[47] Michael R. Green,et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. , 2010, Blood.
[48] Steven J. M. Jones,et al. Recurrent targets of aberrant somatic hypermutation in lymphoma , 2012, Oncotarget.
[49] L. Gordon,et al. Pidilizumab in the treatment of diffuse large B-cell lymphoma , 2014, Expert opinion on biological therapy.
[50] Michael L. Wang,et al. Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications , 2014, Leukemia.
[51] L. Vanuytsel,et al. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] M. Dietrich,et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1 , 2009, Nature Cell Biology.
[53] L. Coussens,et al. Lymphocytes in cancer development: polarization towards pro-tumor immunity. , 2010, Cytokine & growth factor reviews.
[54] A. Roberts,et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). , 2013 .
[55] J. Darnell,et al. The JAK-STAT pathway at twenty. , 2012, Immunity.
[56] Pavel Kovarik,et al. Serine phosphorylation of STATs , 2000, Oncogene.
[57] Olivier Elemento,et al. Epigenomic evolution in diffuse large B-cell lymphomas , 2013, Nature Communications.
[58] B. Coiffier. Rituximab in the treatment of diffuse large B-cell lymphomas. , 2002, Seminars in oncology.
[59] V. Diehl,et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. , 2003, Blood.
[60] J. Friedberg. Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.
[61] Stefano Monti,et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. , 2008, Blood.
[62] L. Gordon,et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] K. Flatten,et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. , 2012, Blood.
[64] Y. Pommier,et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. , 2011, Cancer research.
[65] Hong Zhang,et al. Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma , 2014, Clinical Cancer Research.
[66] L. Staudt,et al. Gene Expression Profiling of Diffuse Large B-Cell Lymphoma , 2003, Leukemia & lymphoma.
[67] E. Yang,et al. Beyond DNA Repair: Additional Functions of PARP-1 in Cancer , 2013, Front. Oncol..
[68] A. Palumbo,et al. 5LBA Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies , 2014 .
[69] N. Schmitz,et al. A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial , 2013 .
[70] J. Simon,et al. Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.
[71] Raul Rabadan,et al. Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.
[72] Li Li,et al. ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen , 2014, Tumor Biology.
[73] L. Pleyer,et al. Digging deep into “dirty” drugs – modulation of the methylation machinery , 2015, Drug metabolism reviews.
[74] D. Demetrick,et al. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. , 2009, Leukemia research.
[75] C. Schmitt,et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. , 2013, Blood.
[76] A. Tarakhovsky,et al. B Cell Immunity Regulated by the Protein Kinase C Family , 2003, Annals of the New York Academy of Sciences.
[77] J. Nair,et al. B cell antigen receptor signaling enhances IFN-gamma-induced Stat1 target gene expression through calcium mobilization and activation of multiple serine kinase pathways. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[78] Derick R. Peterson,et al. Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo , 2012, Molecular Cancer Therapeutics.
[79] N. Chen,et al. Autophagy as a therapeutic target in cancer , 2011, Cancer biology & therapy.
[80] L. Staudt,et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). , 2014 .
[81] L. Staudt,et al. Stromal gene signatures in large-B-cell lymphomas. , 2008, The New England journal of medicine.
[82] J. McMurray,et al. Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression. , 2011, Blood.
[83] K. Horikawa,et al. Toll-Like Receptors and Cancer: MYD88 Mutation and Inflammation , 2014, Front. Immunol..
[84] L. Lam,et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.
[85] R. Gascoyne,et al. CD30 expression in de novo diffuse large B‐cell lymphoma: a population‐based study from British Columbia , 2014, British journal of haematology.
[86] R. Gascoyne,et al. Expression of TRAF1 and Nuclear c-Rel Distinguishes Primary Mediastinal Large Cell Lymphoma From Other Types of Diffuse Large B-cell Lymphoma , 2007, The American journal of surgical pathology.
[87] K. Basso,et al. BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma , 2009, Proceedings of the National Academy of Sciences.
[88] P. Ghia,et al. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. , 2013, Immunology letters.
[89] I. Miura,et al. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.
[90] Bernard Roizman,et al. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[91] E. Cesarman,et al. Molecular characterization of primary mediastinal B cell lymphoma. , 1996, The American journal of pathology.
[92] Yinyin Li,et al. NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4 , 2012, Nature Immunology.
[93] S. Pileri,et al. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma , 2015, Oncotarget.
[94] David A. Orlando,et al. Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.
[95] R. Jaenisch,et al. TET1 is a tumor suppressor of hematopoietic malignancy , 2015, Nature Immunology.
[96] L. Costantino,et al. STAT 3 as a target for cancer drug discovery. , 2008, Current medicinal chemistry.
[97] C. Steidl,et al. Structural genomic alterations in primary mediastinal large B-cell lymphoma , 2015, Leukemia & lymphoma.
[98] P. Gaulard,et al. Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma , 1996 .
[99] B. Bonavida,et al. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. , 2001, Cancer research.
[100] Marietta L. Harrison,et al. Regulation of Signaling in B Cells through the Phosphorylation of Syk on Linker Region Tyrosines , 2002, The Journal of Biological Chemistry.
[101] G. Nowakowski,et al. Evolution: IMiDs to PPMs, revolution in DLBCL? , 2015, Blood.
[102] G. Lenz,et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[103] L. Staudt,et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.
[104] U. Vinkemeier,et al. Nucleocytoplasmic shuttling of STAT transcription factors. , 2004, European journal of biochemistry.
[105] J. Garin,et al. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers , 2013, EMBO molecular medicine.
[106] M. Kitaichi,et al. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[107] Alexandra G. Smith,et al. Epidemiology of lymphomas , 2011, Histopathology.
[108] S. Sacchi,et al. Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma , 2011, Expert opinion on investigational drugs.
[109] C. Gisselbrecht,et al. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. , 2010, Clinical lymphoma, myeloma & leukemia.
[110] A. Rosenwald,et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.
[111] S. Barrans,et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] J. Ruland,et al. Inhibition of MALT1 protease activity is selectively toxic for activated B cell–like diffuse large B cell lymphoma cells , 2009, The Journal of experimental medicine.
[113] Peter M Fischer,et al. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.
[114] E. Stelzer,et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation , 2009, Nature Structural &Molecular Biology.
[115] Shigeo Nakamura,et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. , 2009, Blood.
[116] R. Advani,et al. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). , 2014 .
[117] R. Rickert. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies , 2013, Nature Reviews Immunology.
[118] R. Prinjha,et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. , 2014, Blood.
[119] T. Witzig,et al. Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation. , 2012, Blood.
[120] L. Medeiros,et al. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB-inducing kinase while activating both canonical and alternative nuclear factor-κB pathways. , 2011, Blood.
[121] S. Rosenberg,et al. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. , 2010, Blood.
[122] T. Yeatman,et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells , 2006, Oncogene.
[123] Yixin Zeng,et al. Exome sequencing reveals novel mutation targets in diffuse large B-cell lymphomas derived from Chinese patients. , 2014, Blood.
[124] F. Jardin,et al. Mutation mismatch repair gene deletions in diffuse large B-cell lymphoma , 2013, Leukemia & lymphoma.
[125] Shaji K. Kumar,et al. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. , 2009, Blood.
[126] S. Trudel,et al. Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma. , 2013, Journal of medicinal chemistry.
[127] R. Weichselbaum,et al. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling , 2009, International journal of radiation biology.
[128] R. Gascoyne,et al. MYC and Aggressive B-cell Lymphomas , 2011, Advances in anatomic pathology.
[129] Bianca Nijmeijer,et al. Recognition of mono-ADP-ribosylated ARTD10 substrates by ARTD8 macrodomains. , 2013, Structure.
[130] G. Cheng,et al. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. , 2005, Cancer research.
[131] Laura Pasqualucci,et al. The genetic landscape of diffuse large B-cell lymphoma. , 2015, Seminars in hematology.
[132] A. Deal,et al. FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma , 2015, Science Signaling.
[133] R. Weichselbaum,et al. Molecular Pathways Molecular Pathways : Interferon / Stat 1 Pathway : Role in the Tumor Resistance to Genotoxic Stress and Aggressive Growth , 2012 .
[134] M. Hottiger,et al. ARTD1 Suppresses Interleukin 6 Expression by Repressing MLL1-Dependent Histone H3 Trimethylation , 2015, Molecular and Cellular Biology.
[135] L. Staudt,et al. Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] M. Czuczman,et al. Acquired Resistance to Rituximab Is Associated with Chemotherapy Resistance Resulting from Decreased Bax and Bak Expression , 2008, Clinical Cancer Research.
[137] T. Molina,et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma , 2013, Leukemia.
[138] A. Roberts,et al. The Single-Agent Bcl-2 Inhibitor ABT-199 (GDC-0199) In Patients With Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Responses Observed In All Mantle Cell Lymphoma (MCL) Patients , 2013 .
[139] F. Cabanillas,et al. Epigenetic therapy of lymphoma using histone deacetylase inhibitors , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[140] L. Staudt,et al. Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma , 2003, The Journal of experimental medicine.
[141] Takashi Watanabe. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas , 2010, Expert opinion on investigational drugs.
[142] F. Lanza,et al. Ibrutinib: from bench side to clinical implications , 2015, Medical Oncology.
[143] A. Mansoor,et al. pY-STAT3 and p53 expression predict outcome for poor prognosis diffuse large B-cell lymphoma treated with high dose chemotherapy and autologous stem cell transplantation , 2009, Leukemia & lymphoma.
[144] C. Steidl,et al. Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma. , 2015, Seminars in hematology.
[145] R. Aguiar,et al. Targeting of SMAD5 links microRNA-155 to the TGF-β pathway and lymphomagenesis , 2010, Proceedings of the National Academy of Sciences.
[146] S. Goenka,et al. PARP-14 Functions as a Transcriptional Switch for Stat6-dependent Gene Activation* , 2010, The Journal of Biological Chemistry.
[147] W. Parson,et al. Replenishment of the B cell compartment after doxorubicin‐induced hematopoietic toxicity is facilitated by STAT1 , 2014, Journal of leukocyte biology.
[148] J. Pascal,et al. Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling , 2013, Molecular Aspects of Medicine.
[149] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[150] L. Larocca,et al. Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma , 2012, Leukemia & lymphoma.
[151] S. Dewilde,et al. The immediate early genes Fos and Egr1 become STAT1 transcriptional targets in the absence of STAT3 , 2011, FEBS letters.
[152] D. Federman,et al. The epidemiology of non-Hodgkin's lymphoma. , 1996, Connecticut medicine.
[153] S. Yoon,et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B‐cell lymphoma (DLBCL), especially in germinal centre‐like B cell (GCB) type , 2008, Histopathology.
[154] J. ten Hoeve,et al. A transcriptional corepressor of Stat1 with an essential LXXLL signature motif , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[155] W. Wilson,et al. Drug resistance in diffuse large B-cell lymphoma. , 2006, Seminars in hematology.
[156] J. Byrd,et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.
[157] V. Papadopoulou,et al. Poly-(ADP-ribose) polymerase-1 (Parp-1) binds in a sequence-specific manner at the Bcl-6 locus and contributes to the regulation of Bcl-6 transcription , 2007, Oncogene.
[158] D. Schenkein. Proteasome inhibitors in the treatment of B-cell malignancies. , 2002, Clinical lymphoma.
[159] R. Advani,et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[160] Steven J. M. Jones,et al. Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.
[161] Michael R. Green,et al. Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy , 2012, Clinical Cancer Research.
[162] T. Golub,et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.
[163] S. Grant,et al. Circumvention of Mcl-1-Dependent Drug Resistance by Simultaneous Chk1 and MEK1/2 Inhibition in Human Multiple Myeloma Cells , 2014, PloS one.
[164] D. Baker,et al. Host STAT2/type I interferon axis controls tumor growth , 2015, International journal of cancer.
[165] G. Salles,et al. Treatment approach to newly diagnosed diffuse large B-cell lymphoma. , 2015, Seminars in hematology.
[166] G. Lenz,et al. Critical role of PI3K signaling for NF-κB–dependent survival in a subset of activated B-cell–like diffuse large B-cell lymphoma cells , 2010, Proceedings of the National Academy of Sciences.
[167] Christopher J. Ott,et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.
[168] R. Gascoyne,et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. , 2014, Blood.
[169] P. de Paepe,et al. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities , 2007, Leukemia.
[170] D. Olive,et al. Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity , 2003, Leukemia.
[171] R. Fisher. Diffuse large-cell lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[172] T. Ashizawa,et al. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. , 2011, International journal of oncology.
[173] Robert Tibshirani,et al. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. , 2003, Blood.
[174] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[175] C. Burgaleta,et al. Two‐weekly dose‐adjusted (DA)‐EPOCH‐like chemotherapy with high‐dose dexamethasone plus rituximab (DA‐EDOCH14‐R) in poor‐prognostic untreated diffuse large B‐cell lymphoma , 2013, British journal of haematology.
[176] B. Cairns,et al. HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma , 2014, Oncotarget.
[177] Alexander D. MacKerell,et al. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. , 2010, Cancer cell.
[178] W. Wilson,et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[179] A. Rosenwald,et al. MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .
[180] S. Neelapu,et al. ABCG2 is a Direct Transcriptional Target of Hedgehog Signaling and Involved in Stroma-Induced Drug Tolerance in Diffuse Large B-Cell Lymphoma , 2011, Oncogene.
[181] K. Kita,et al. Involvement of LEU13 in Interferon-Induced Refractoriness of Human RSa Cells to Cell Killing by X Rays , 2003, Radiation research.
[182] J Diebold,et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.
[183] Sadik H. Kassim,et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[184] R. Copeland,et al. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas , 2014, PloS one.
[185] J. Walling,et al. A purine scaffold Hsp90 inhibitor destabilizes Bcl6 and has specific anti-tumor activity in Bcl6 dependent B-cell lymphomas , 2009, Nature Medicine.
[186] S. Swerdlow,et al. Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas , 2013, The American journal of surgical pathology.
[187] L. Staudt. Oncogenic activation of NF-kappaB. , 2010, Cold Spring Harbor perspectives in biology.
[188] S. Chew,et al. Genome-wide association study of B cell non-Hodgkin lymphoma identifies 3q27 as a susceptibility locus in the Chinese population , 2013, Nature Genetics.
[189] K. Anderson,et al. Gene expression analysis of B‐lymphoma cells resistant and sensitive to bortezomib * , 2006, British journal of haematology.
[190] H. Bluyssen,et al. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity. , 2013, European journal of pharmacology.
[191] R. Gascoyne,et al. BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. , 2010, The Journal of clinical investigation.
[192] J. Vose,et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[193] F. Alt,et al. An oncogenic role for alternative NF-κB signaling in DLBCL revealed upon deregulated BCL6 expression. , 2015, Cell reports.
[194] P. Bouillet,et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. , 2014, Leukemia.
[195] J. Cigudosa,et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. , 1998, Blood.
[196] K. Dunleavy. Double-hit lymphomas: current paradigms and novel treatment approaches. , 2014, Hematology. American Society of Hematology. Education Program.
[197] Sonali M. Smith,et al. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. , 2010, Blood cells, molecules & diseases.
[198] F. Jardin,et al. The isotype of the BCR as a surrogate for the GCB and ABC molecular subtypes in diffuse large B-cell lymphoma , 2011, Leukemia.
[199] A. Isaksson,et al. Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles , 2005, British Journal of Cancer.
[200] A. Melnick,et al. Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment? , 2013, Expert review of hematology.
[201] T. Rebbeck,et al. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma. , 2007, Blood.
[202] R. Weichselbaum,et al. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect , 2009, BMC medicine.
[203] Jordi Martínez,et al. GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II study , 2007, European journal of haematology.
[204] W. Choi,et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. , 2013, Blood.
[205] F. Russo,et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: Results of a pilot study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[206] X. Thomas,et al. Antibody‐based therapies in B‐cell lineage acute lymphoblastic leukaemia , 2015, European journal of haematology.
[207] Eric S. Lander,et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing , 2012, Proceedings of the National Academy of Sciences.
[208] M. Shipp,et al. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. , 2005, Blood.
[209] Sam Michael,et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells , 2014, Proceedings of the National Academy of Sciences.
[210] Juswinder Singh,et al. Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[211] Timothy C Greiner,et al. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. , 2012, Blood.
[212] Bernhard Lüscher,et al. Macrodomain-containing proteins: regulating new intracellular functions of mono(ADP-ribosyl)ation , 2013, Nature Reviews Molecular Cell Biology.
[213] P. Venugopal,et al. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. , 2007, Clinical lymphoma & myeloma.
[214] J. Walker,et al. Fold of the conserved DTC domain in deltex proteins , 2012, Proteins.
[215] O. O’Connor,et al. Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. , 2013, Blood.
[216] M. Kizaki,et al. Loss of HLA-DR expression is related to tumor microenvironment and predicts adverse outcome in diffuse large B-cell lymphoma , 2016, Leukemia & lymphoma.
[217] D. Scott,et al. IL10 receptor is a novel therapeutic target in DLBCLs , 2015, Leukemia.
[218] Rebecca L. Lamason,et al. Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. , 2010, Biochemistry.
[219] J. Noel,et al. Abstract C244: Development of the BET bromodomain inhibitor OTX015. , 2013 .
[220] D. Sabatini,et al. Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.
[221] K. Basso,et al. Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.
[222] J. Vose,et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[223] Tim J. Wigle,et al. Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.
[224] P. Worland,et al. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization , 2015, Molecular Cancer Therapeutics.
[225] Ryan D. Morin,et al. An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup. , 2015, Blood.
[226] T. Lister,et al. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. , 2007, Cancer research.
[227] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[228] K. Mazan-Mamczarz,et al. Article title: Inhibiting CARD11 translation during BCR activation by targeting the eIF4A RNA helicase , 2017 .
[229] J. Hainsworth,et al. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[230] R. Warnke,et al. Mutational Analysis of IgVH and BCL-6 Genes Suggests Thymic B-cells Origin of Mediastinal (Thymic) B-cell Lymphoma , 2004, Leukemia & lymphoma.
[231] J H Goldie,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.
[232] Wei Gu,et al. Acetylation inactivates the transcriptional repressor BCL6 , 2002, Nature Genetics.
[233] N. Rajewsky,et al. Survival of Resting Mature B Lymphocytes Depends on BCR Signaling via the Igα/β Heterodimer , 2004, Cell.
[234] W. Chan,et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B‐cell lymphoma treated with rituximab , 2014, British journal of haematology.
[235] Y Lynn Wang,et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. , 2011, Blood.
[236] K. Rajewsky,et al. Aberrant B Cell Development and Immune Response in Mice with a Compromised BCR Complex , 1996, Science.
[237] Rajen Dinesh Shah,et al. Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[238] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[239] T. Mak,et al. Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function , 1997, Science.
[240] O. Elemento,et al. EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains , 2013 .
[241] H. Sanjo,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[242] Lai Wei,et al. Interferon-resistant Daudi Cell Line with a Stat2 Defect Is Resistant to Apoptosis Induced by Chemotherapeutic Agents* , 2009, The Journal of Biological Chemistry.
[243] Jennifer R. Brown. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies , 2014, Leukemia and Lymphoma.
[244] R. Gascoyne,et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[245] R. Herbst,et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[246] I. Giannopoulou,et al. Prognostic significance of phosphorylated STAT‐1 expression in premenopausal and postmenopausal patients with invasive breast cancer , 2012, Histopathology.
[247] M. Czuczman,et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[248] Bingshu E. Chen,et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[249] G. Schäfer,et al. IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 , 2013, Endocrine-related cancer.
[250] T. Rülicke,et al. STAT1β Is Not Dominant Negative and Is Capable of Contributing to Gamma Interferon-Dependent Innate Immunity , 2014, Molecular and Cellular Biology.
[251] R. Gascoyne,et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. , 2012, Cancer cell.
[252] L. Staudt,et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study , 2012 .
[253] L. Staudt,et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. , 2009, Blood.
[254] Adrien B. Larsen,et al. Loss of signaling via Gα13 in germinal center B cell-derived lymphoma , 2014, Nature.
[255] Govind Bhagat,et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. , 2010, Cancer cell.
[256] Z. Ni,et al. The chromatin-remodeling enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers , 2008, Nature Immunology.
[257] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[258] Michael L. Wang,et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[259] Yang Liu,et al. Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. , 2014, Clinical immunology.
[260] Diana Anderson,et al. In vitro studies of DNA damage and its repair in cells from NHL patients with different p53 mutant protein status, resistant (p53(+)) and sensitive (p53(-)) to cancer chemotherapy. , 2007, Journal of pharmacological and toxicological methods.
[261] E. Suzuki,et al. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis , 2007, Oncogene.
[262] P. Nowell. The clonal evolution of tumor cell populations. , 1976, Science.
[263] L. Rimsza,et al. Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1 , 2015, Leukemia.
[264] W. Wilson,et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype , 2012, Haematologica.
[265] W. Wilson,et al. Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor , 2009, Journal of immunotherapy.
[266] L. Staudt,et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. , 2006, Blood.
[267] K. Rajewsky,et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[268] T. Mustelin,et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-β II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN , 2007, Leukemia & lymphoma.
[269] R. Lock,et al. The role of IRF1 and IRF2 transcription factors in leukaemogenesis. , 2006, Current gene therapy.
[270] Philip M Kluin,et al. Double-hit B-cell lymphomas. , 2011, Blood.
[271] K. Al-Kuraya,et al. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. , 2005, Blood.
[272] K. Akashi,et al. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma. , 2015, Blood.
[273] M. Czuczman,et al. Higher response to lenalidomide in relapsed/refractory diffuse large B‐cell lymphoma in nongerminal center B‐cell–like than in germinal center B‐cell–like phenotype , 2011, Cancer.
[274] C. Shapiro,et al. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells , 2012, Breast Cancer Research and Treatment.
[275] I. Lödige,et al. Nuclear Export Determines the Cytokine Sensitivity of STAT Transcription Factors* , 2005, Journal of Biological Chemistry.
[276] J. Briones,et al. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma , 2006, Annals of Hematology.
[277] L. Staudt,et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[278] F. Jardin,et al. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes , 2012, Genes, chromosomes & cancer.
[279] F. Allain,et al. RRM-RNA recognition: NMR or crystallography…and new findings. , 2013, Current opinion in structural biology.
[280] A. Younes,et al. Novel targeted therapies in diffuse large B-cell lymphoma. , 2015, Seminars in hematology.
[281] M. Mokry,et al. FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. , 2014, Blood.
[282] W. Wilson,et al. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? , 2015, Blood.
[283] Juthamas Sukbuntherng,et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. , 2013, The New England journal of medicine.
[284] G. Pinkus,et al. Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain , 2014, The American journal of surgical pathology.
[285] R. Advani,et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. , 2015, Blood.
[286] Manish R. Patel,et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. , 2015, The Lancet. Oncology.
[287] Y. Herishanu,et al. Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond , 2014, Leukemia & lymphoma.
[288] Steven J. M. Jones,et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers , 2011, Nature.
[289] D. Sterner,et al. Discovery of Therapeutic Deubiquitylase Effector Molecules , 2014, Journal of biomolecular screening.
[290] M. Smyth,et al. Supernatural T cells: genetic modification of T cells for cancer therapy , 2005, Nature Reviews Immunology.
[291] Thomas Helleday,et al. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.
[292] Michael L. Wang,et al. Accelerated therapeutic progress in diffuse large B cell lymphoma , 2014, Annals of Hematology.
[293] T. Taniguchi,et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). , 1995, Nucleic acids research.
[294] A. Intlekofer,et al. Precision therapy for lymphoma—current state and future directions , 2014, Nature Reviews Clinical Oncology.
[295] Liming Yang,et al. A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.
[296] Paul Shinn,et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.
[297] G. Shore,et al. Modulating the bcl-2 family of apoptosis suppressors for potential therapeutic benefit in cancer. , 2005, Hematology. American Society of Hematology. Education Program.
[298] J. Monroe,et al. Analysis of the Individual Contributions of Igα (CD79a)- and Igβ (CD79b)-Mediated Tonic Signaling for Bone Marrow B Cell Development and Peripheral B Cell Maturation1 , 2006, The Journal of Immunology.
[299] C. Billard. BH3 Mimetics: Status of the Field and New Developments , 2013, Molecular Cancer Therapeutics.
[300] R. Siebert,et al. Molecular analysis of single B cells from T-cell-rich B-cell lymphoma shows the derivation of the tumor cells from mutating germinal center B cells and exemplifies means by which immunoglobulin genes are modified in germinal center B cells. , 1999, Blood.
[301] Yulan Qing,et al. Alternative Activation of STAT1 and STAT3 in Response to Interferon-γ* , 2004, Journal of Biological Chemistry.
[302] A. Verma,et al. Linked-In: Design and Efficacy of Antibody Drug Conjugates in Oncology , 2013, Oncotarget.
[303] Karen Leroy,et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. , 2004, Blood.
[304] Wenqing Xu,et al. Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitination. , 2012, Genes & development.
[305] W. Wilson,et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. , 2010, Blood.
[306] Roland Schmitz,et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma , 2015, Nature Medicine.
[307] W. Wilson,et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. , 2012, Blood.
[308] S. Korsmeyer,et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.
[309] M. Hottiger,et al. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. , 2008, Frontiers in bioscience : a journal and virtual library.
[310] Hua Yu,et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. , 2011, Cancer research.
[311] S. Maeda,et al. IκB kinase β–induced phosphorylation of CARMA1 contributes to CARMA1–Bcl10–MALT1 complex formation in B cells , 2007, The Journal of experimental medicine.
[312] G. Romeo,et al. IRF-1 as a negative regulator of cell proliferation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[313] S. Monti,et al. Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas , 2012, PloS one.
[314] P. Raman,et al. The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. , 2013, Blood.
[315] M. Jerkeman,et al. Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients , 2010, Modern Pathology.
[316] T. Decker,et al. Phosphorylation of the Stat1 transactivating domain is required for the response to type I interferons , 2003, EMBO reports.
[317] M. Shipp. Molecular signatures define new rational treatment targets in large B-cell lymphomas. , 2007, Hematology. American Society of Hematology. Education Program.
[318] C. Gisselbrecht. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma? , 2012, Hematology. American Society of Hematology. Education Program.
[319] I. Lossos,et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. , 2007, Blood.
[320] E. Jaffe,et al. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. , 2009, Hematology. American Society of Hematology. Education Program.
[321] Gordon B Mills,et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.
[322] J. Delabie,et al. T-cell/histiocyte-rich large B-cell lymphoma shows transcriptional features suggestive of a tolerogenic host immune response , 2010, Haematologica.
[323] Jun Zhu,et al. High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma , 2011, Journal of hematology & oncology.
[324] A. Zelenetz,et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. , 2004, Blood.
[325] R. Larsson,et al. Image-Based Screening for the Identification of Novel Proteasome Inhibitors , 2007, Journal of biomolecular screening.
[326] M. Dogan,et al. Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP , 2010, Medical oncology.
[327] B. Druker,et al. A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor , 2014, Oncotarget.
[328] T. Golub,et al. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. , 2013, Cancer cell.
[329] A. Zelenetz,et al. Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[330] Bernhard Lüscher,et al. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. , 2010, Trends in biochemical sciences.
[331] G. Lenz,et al. IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL. , 2013, Blood.
[332] J. Armitage,et al. Primary mediastinal large B-cell lymphoma. , 2015, Cancer treatment reviews.
[333] Ricardo C T Aguiar,et al. The BAL-binding Protein BBAP and Related Deltex Family Members Exhibit Ubiquitin-Protein Isopeptide Ligase Activity* , 2003, Journal of Biological Chemistry.
[334] J. Hayes. Population-attributable risks for modifiable lifestyle factors and breast cancer in New Zealand women. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[335] H. Okano,et al. Murine homologs of deltex define a novel gene family involved in vertebrate Notch signaling and neurogenesis , 2001, International Journal of Developmental Neuroscience.
[336] D. Porter,et al. Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas. , 2015 .
[337] S. Hilsenbeck,et al. Selective Small Molecule Stat3 Inhibitor Reduces Breast Cancer Tumor-Initiating Cells and Improves Recurrence Free Survival in a Human-Xenograft Model , 2012, PloS one.
[338] R. Chopra,et al. Lenalidomide efficacy in activated B‐cell‐like subtype diffuse large B‐cell lymphoma is dependent upon IRF4 and cereblon expression , 2012, British journal of haematology.
[339] J. Radford,et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma , 2015, Leukemia and Lymphoma.
[340] E. Vellenga,et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. , 2006, Blood.
[341] A. Glass,et al. The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells. , 2012, Anticancer research.
[342] A. Rosenwald,et al. Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.
[343] M. Pfreundschuh,et al. Management of diffuse large B-cell lymphoma (DLBCL). , 2015, Cancer treatment and research.
[344] Dereje D. Jima,et al. PAK1 Mediates Resistance to PI3K Inhibition in Lymphomas , 2013, Clinical Cancer Research.
[345] J. Turkson,et al. Cell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells , 2004, Oncogene.
[346] S. Knapp,et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. , 2013, Cancer research.
[347] L. Staudt,et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. , 2008, Blood.
[348] A. Mottok,et al. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities. , 2009, Blood.
[349] I. Yajima,et al. Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway , 2015, Oncotarget.
[350] R. Knight,et al. STAT-1 Interacts with p53 to Enhance DNA Damage-induced Apoptosis* , 2004, Journal of Biological Chemistry.
[351] Jan Delabie,et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma , 2010, Nature.
[352] A. Olshen,et al. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response , 2008, Leukemia & lymphoma.
[353] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[354] H. Stein,et al. A novel A20 (TNFAIP3) antibody (Ber‐A20) can be used to detect unmutated A20 by immunohistology , 2012, Histopathology.
[355] R. Gascoyne,et al. The tumour microenvironment in B cell lymphomas , 2014, Nature Reviews Cancer.
[356] Charles Y. Lin,et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. , 2013, Cancer cell.
[357] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[358] L. Ysebaert,et al. Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies , 2011, Expert opinion on investigational drugs.
[359] Anders Poulsen,et al. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lympho , 2011, Journal of medicinal chemistry.
[360] I. Pastan,et al. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion , 2012, Haematologica.
[361] Steven J. M. Jones,et al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. , 2013, Blood.
[362] W. Guida,et al. A novel inhibitor of STAT3 homodimerization selectively suppresses STAT3 activity and malignant transformation. , 2013, Cancer research.
[363] R. Gascoyne,et al. Lymphoma stem cells: enough evidence to support their existence? , 2010, Haematologica.
[364] A. Chaidos,et al. Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma , 2012, Oncogene.
[365] L. Staudt,et al. B-cell receptor signaling in diffuse large B-cell lymphoma. , 2015, Seminars in hematology.
[366] Michael L. Wang,et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. , 2013, The New England journal of medicine.
[367] C. Tse,et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.
[368] Yasodha Natkunam,et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.
[369] L. Staudt,et al. Diffuse large B-cell lymphoma—treatment approaches in the molecular era , 2014, Nature Reviews Clinical Oncology.
[370] H. Gerber,et al. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. , 2015, Molecular immunology.
[371] David E Levy,et al. STAT1 acts as a tumor promoter for leukemia development. , 2006, Cancer cell.
[372] M. Lenarz,et al. Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma , 2014, Leukemia & lymphoma.
[373] J. Bromberg,et al. Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[374] Raul Rabadan,et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.
[375] Ash A. Alizadeh,et al. Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[376] M. Mraz,et al. MicroRNAs in B-cell lymphomas: how a complex biology gets more complex , 2014, Leukemia.
[377] M. David,et al. Regulation of STAT1 Nuclear Export by Jak1 , 2000, Molecular and Cellular Biology.
[378] F. Baran-Marszak,et al. Differential roles of STAT1alpha and STAT1beta in fludarabine-induced cell cycle arrest and apoptosis in human B cells. , 2004, Blood.
[379] J. Maciejewski,et al. HDAC inhibitors potentiate the apoptotic effect of enzastaurin in lymphoma cells , 2011, Apoptosis.
[380] J. DiGiovanni,et al. A novel mechanism of skin tumor promotion involving interferon‐gamma (IFNγ)/signal transducer and activator of transcription‐1 (Stat1) signaling , 2015, Molecular carcinogenesis.
[381] W. Wilson,et al. Cracking the diverse biologic code of diffuse large B-cell lymphoma. , 2015, Seminars in hematology.
[382] L. Trusolino,et al. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited. , 2014, Biochimica et biophysica acta.
[383] A. Roberts,et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma: responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. , 2014, Clinical advances in hematology & oncology : H&O.
[384] L. Staudt,et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[385] P. Gaulard,et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.
[386] R. Pearson,et al. AKT signalling is required for ribosomal RNA synthesis and progression of Eμ‐Myc B‐cell lymphoma in vivo , 2013, The FEBS journal.
[387] C. Tse,et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo , 2008, Molecular Cancer Therapeutics.
[388] P. Juszczyński,et al. Host immune response in B-cell lymphomas: friend or foe? , 2008, Archivum Immunologiae et Therapiae Experimentalis.
[389] S. Kaufmann,et al. PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.
[390] K. Young,et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[391] Ryan D. Morin,et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.
[392] G. Lenz,et al. Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines , 2011, Proceedings of the National Academy of Sciences.
[393] A. Santoro,et al. CC-122 Degrades the Lymphoid Transcription Factor Aiolos (IKZF3) By Modulating Cereblon and Shows Clinical Activity in a Phase Ib Study of Subjects with Relapsed or Refractory Non-Hodgkin’s Lymphoma and Multiple Myeloma , 2014 .
[394] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[395] K. Myung,et al. A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress , 2015, Nucleic acids research.
[396] K. Jang,et al. SIRT1 Expression is Associated With Poor Prognosis of Diffuse Large B-Cell Lymphoma , 2008, The American journal of surgical pathology.
[397] Larry Rubinstein,et al. A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas , 2012, Clinical Cancer Research.
[398] B. Bonavida,et al. Rituximab-Induced Inhibition of YY1 and Bcl-xL Expression in Ramos Non-Hodgkin’s Lymphoma Cell Line via Inhibition of NF-κB Activity: Role of YY1 and Bcl-xL in Fas Resistance and Chemoresistance, Respectively1 , 2005, The Journal of Immunology.
[399] M. Dyer,et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.
[400] J. Aster,et al. Deltex1 redirects lymphoid progenitors to the B cell lineage by antagonizing Notch1. , 2002, Immunity.
[401] R. Aguiar,et al. MicroRNA-155 controls RB phosphorylation in normal and malignant B lymphocytes via the noncanonical TGF-β1/SMAD5 signaling module. , 2014, Blood.
[402] E. D. Jacobsen,et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[403] J. Qi,et al. Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells , 2014, Molecular Cancer Therapeutics.
[404] B. Bonavida,et al. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention , 2005, Oncogene.
[405] T. Golub,et al. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. , 2005, Blood.
[406] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[407] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[408] J. Friedberg,et al. PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1–Dependent Mechanisms In Vitro and In Vivo , 2014, Clinical Cancer Research.
[409] A. Letai,et al. BCL2 suppresses PARP1 function and nonapoptotic cell death. , 2012, Cancer research.
[410] Goldie Jh,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .
[411] R. Gascoyne,et al. Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease? , 2013, PloS one.
[412] S. Rosenberg,et al. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors , 2013, Nature Reviews Clinical Oncology.
[413] E. Campo,et al. MYC alterations in diffuse large B-cell lymphomas. , 2015, Seminars in hematology.
[414] L. Monasta,et al. NF-κB pathways in hematological malignancies , 2014, Cellular and Molecular Life Sciences.
[415] A. Melnick,et al. Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma , 2013, Clinical Cancer Research.
[416] M. Shipp,et al. BAL1 and Its Partner E3 Ligase, BBAP, Link Poly(ADP-Ribose) Activation, Ubiquitylation, and Double-Strand DNA Repair Independent of ATM, MDC1, and RNF8 , 2012, Molecular and Cellular Biology.
[417] K. Flaherty,et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[418] L. Staudt,et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. , 2005, Blood.
[419] Aggressive lymphomas. , 2010, The New England journal of medicine.
[420] T. Habermann,et al. Patients Enrolled in the Gimema Lal 0496 Protocol Presentation and Correlation with Response to Induction Treatment in Adult T-cell Acute Lymphoblastic Leukemia: Biologic Profile At , 2005 .
[421] W. Dalton,et al. The tumor microenvironment shapes hallmarks of mature B-cell malignancies , 2015, Oncogene.
[422] Peter Martin,et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[423] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[424] L. Staudt,et al. BCL2 Predicts Survival in Germinal Center B-cell–like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab , 2011, Clinical Cancer Research.
[425] V. Pavone,et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. , 2014, The Lancet. Oncology.
[426] J. Ruland,et al. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.
[427] E. Giné,et al. Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[428] Wei Gu,et al. p53 post-translational modification: deregulated in tumorigenesis. , 2010, Trends in molecular medicine.
[429] L. Goodglick,et al. Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab , 2004, Cancer Research.
[430] Pier Paolo Pandolfi,et al. Tenets of PTEN Tumor Suppression , 2008, Cell.
[431] L. Staudt,et al. Pathogenesis of human B cell lymphomas. , 2012, Annual review of immunology.
[432] B. Bonavida,et al. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. , 2007, Cancer research.
[433] C. Meijer,et al. Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B‐cell lymphoma , 2006, Hematological oncology.
[434] Arthur Weiss,et al. The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathways , 1991, Cell.
[435] L. Gordon,et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[436] T. Golub,et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. , 2004, Blood.
[437] L. Vanuytsel,et al. Histiocyte‐rich, T‐cell‐rich B‐cell lymphoma: a distinct diffuse large B‐cell lymphoma subtype showing characteristic morphologic and immunophenotypic features , 2002, Histopathology.
[438] S. Artavanis-Tsakonas,et al. Human deltex is a conserved regulator of Notch signalling , 1998, Nature Genetics.
[439] Nallasivam Palanisamy,et al. Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas. , 2004, Blood.
[440] M. Kuehl,et al. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB , 2014, Oncotarget.
[441] DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells , 2014, Molecular Cancer.
[442] Yuan-Xiao Zhu,et al. Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma , 2015, Haematologica.
[443] Sara Spjut,et al. Towards small molecule inhibitors of mono-ADP-ribosyltransferases. , 2015, European journal of medicinal chemistry.
[444] R. Bende,et al. Expression of activation-induced cytidine deaminase is confined to B-cell non-Hodgkin's lymphomas of germinal-center phenotype. , 2003, Cancer research.
[445] K. Tarte,et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial , 2014, Leukemia.
[446] D. Faller,et al. Tumor-specific and Proliferation-specific Gene Expression Typifies Murine Transgenic B Cell Lymphomagenesis* , 2007, Journal of Biological Chemistry.
[447] Jan Delabie,et al. Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma , 2008, Science.
[448] W. Dalton,et al. The Bone Marrow Microenvironment as a Tumor Sanctuary and Contributor to Drug Resistance , 2008, Clinical Cancer Research.
[449] Renhao Li,et al. Specific Inhibition Of Ectodomain Shedding Of GPIba By Targeting Its Shedding Cleavage Site , 2013 .
[450] J. Bujnicki,et al. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. , 2011, Cytokine & growth factor reviews.
[451] T. Habermann,et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study , 2011, Leukemia.
[452] Gwendoline Dubois,et al. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. , 2009, Blood.
[453] L. Aravind. The WWE domain: a common interaction module in protein ubiquitination and ADP ribosylation. , 2001, Trends in biochemical sciences.
[454] D. Barrick,et al. Structure and Notch receptor binding of the tandem WWE domain of Deltex. , 2005, Structure.
[455] Tara L. Naylor,et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. , 2011, Cancer research.
[456] Ronald Levy,et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. , 2010, Blood.
[457] W. Grody,et al. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma. , 2002, Clinical lymphoma.
[458] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[459] D. Fruman,et al. Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1 , 2014, PloS one.
[460] A. Lukacher. IFN-γ suspends the killing license of anti-tumor CTLs , 2002 .
[461] R. Plummer,et al. Progress in the Function and Regulation of ADP-Ribosylation , 2011, Science Signaling.
[462] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[463] J. Tschopp,et al. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF-κB target genes. , 2012, Molecular cell.
[464] L. Staudt,et al. The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.
[465] S. Perkins,et al. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. , 2000, American journal of clinical pathology.
[466] R. Mesa,et al. Janus kinase inhibitors for the treatment of myeloproliferative neoplasms , 2014, Expert opinion on pharmacotherapy.
[467] R. DePinho,et al. PI3 Kinase Signals BCR-Dependent Mature B Cell Survival , 2009, Cell.
[468] Yan Liu,et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.
[469] Seth M Steinberg,et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.
[470] Christian Steidl,et al. Cooperative epigenetic modulation by cancer amplicon genes. , 2010, Cancer cell.
[471] P. Richardson,et al. Dual Inhibition of Canonical and Noncanonical NF-κB Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma , 2012, Clinical Cancer Research.
[472] V. Pavone,et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi , 2013, Haematologica.
[473] K. Basso,et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. , 2007, Cancer cell.
[474] Alejandro Martín,et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study , 2008, Haematologica.
[475] T. Habermann,et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma , 2010, Leukemia.
[476] R. Fisher,et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: a Southwest Oncology Group Study. , 2001, Journal of Clinical Oncology.
[477] M. Schuler,et al. Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention , 2009, Leukemia & lymphoma.
[478] J. Kobarg,et al. Detection and Possible Prognostic Relevance of p53 Gene Mutations in Diffuse Large B-cell Lymphoma. An Analysis of 51 Cases and Review of the Literature , 2004, Leukemia & lymphoma.
[479] C. Rosenfeld,et al. Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies. , 2003, Current opinion in investigational drugs.
[480] G. Pinkus,et al. Programmed Death Ligand 1 Is Expressed by Non–Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells , 2011, Clinical Cancer Research.
[481] T. Witzig,et al. Signal transduction inhibitor therapy for lymphoma. , 2010, Hematology. American Society of Hematology. Education Program.
[482] R. Gascoyne,et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. , 2013, Blood.
[483] C. la Vecchia,et al. Cancer mortality in the European Union, 1988–1997: The fall may approach 80,000 deaths a year , 2002, International journal of cancer.
[484] K. Opeskin,et al. Protein kinase C-beta II expression in diffuse large B-cell lymphoma predicts for inferior outcome of anthracycline-based chemotherapy with and without rituximab , 2009, Leukemia & lymphoma.
[485] P. Gaulard,et al. Pathobiology of Primary Mediastinal B-Cell Lymphoma , 2003, Leukemia & lymphoma.
[486] S. Sakajiri,et al. Identification of CD20 C-Terminal Deletion Mutations Associated with Loss of CD20 Expression in Non-Hodgkin's Lymphoma , 2009, Clinical Cancer Research.
[487] A. Melnick,et al. A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. , 2009, Blood.
[488] C. Crews,et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.
[489] B. Zwilling,et al. Mycobacterium avium Inhibition of IFN-γ Signaling in Mouse Macrophages: Toll-Like Receptor 2 Stimulation Increases Expression of Dominant-Negative STAT1β by mRNA Stabilization 1 , 2003, The Journal of Immunology.
[490] A. Harel-Bellan,et al. The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity. , 2006, Genes & development.
[491] William Arbuthnot Sir Lane,et al. Acetylation of Poly(ADP-ribose) Polymerase-1 by p300/CREB-binding Protein Regulates Coactivation of NF-κB-dependent Transcription* , 2005, Journal of Biological Chemistry.
[492] J C Reed,et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.
[493] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[494] P. Linsley,et al. Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ , 2012, Apoptosis.
[495] A. Lukacher. IFN-gamma suspends the killing license of anti-tumor CTLs. , 2002, The Journal of clinical investigation.
[496] S. Cory,et al. ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. , 2013, Blood.
[497] G. Saglio,et al. Molecular pathogenesis of diffuse large B-cell lymphoma , 2009 .
[498] J. Kutok,et al. BAL1 and BBAP Are Regulated by a Gamma Interferon-Responsive Bidirectional Promoter and Are Overexpressed in Diffuse Large B-Cell Lymphomas with a Prominent Inflammatory Infiltrate , 2006, Molecular and Cellular Biology.
[499] J. D. Di Santo,et al. The intrathymic crossroads of T and NK cell differentiation , 2010, Immunological reviews.
[500] P. Trojer,et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. , 2014, Chemistry & biology.
[501] Elias Campo,et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. , 2011, Blood.
[502] J. Tao,et al. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies , 2014, Oncogene.
[503] J. Aster,et al. The double-edged sword of Notch signaling in cancer. , 2012, Seminars in cell & developmental biology.
[504] N. Schmitz,et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[505] A. Ng,et al. Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.
[506] F. Baran-Marszak,et al. Novel function of STAT1β in B cells: induction of cell death by a mechanism different from that of STAT1α , 2008, Journal of leukocyte biology.
[507] A. Mattevi,et al. Differential Properties of Transcriptional Complexes Formed by the CoREST Family , 2014, Molecular and Cellular Biology.
[508] C. Gisselbrecht,et al. Relapses, treatments and new drugs. , 2012, Best practice & research. Clinical haematology.
[509] P. L. Bergsagel,et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. , 2011, Blood.
[510] N. Rajewsky,et al. Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. , 2004, Cell.
[511] Douglas H. Thamm,et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy , 2010, Proceedings of the National Academy of Sciences.
[512] A. Poulsen,et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies , 2011, Leukemia.
[513] Anastasis Stephanou,et al. STAT‐1: a novel regulator of apoptosis , 2003, International journal of experimental pathology.
[514] B. Hill,et al. Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients , 2015, Leukemia & lymphoma.
[515] Hadassa Klerman,et al. QKI-Mediated Alternative Splicing of the Histone Variant MacroH2A1 Regulates Cancer Cell Proliferation , 2011, Molecular and Cellular Biology.
[516] Sadik H. Kassim,et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. , 2013, Blood.
[517] K. Opeskin,et al. Protein Kinase C Beta II Expression in Diffuse Large B-Cell Lymphoma Predicts for Inferior Outcome of Anthracycline-Based Chemotherapy With And Without Rituximab , 2009 .
[518] A. Younes,et al. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib , 2013, Expert opinion on investigational drugs.
[519] A. Lazar,et al. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance. , 2012, Cancer research.
[520] Adrian Wiestner,et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[521] R. Gascoyne,et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.
[522] S. Grosskurth,et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma , 2014, Oncotarget.
[523] Markus Loeffler,et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.
[524] L. Staudt,et al. Targeting pathological B cell receptor signalling in lymphoid malignancies , 2013, Nature Reviews Drug Discovery.
[525] J. Abramson. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. , 2006, The oncologist.
[526] S. Monti,et al. Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo , 2014, Clinical Cancer Research.
[527] L. Staudt,et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.
[528] M. Shipp,et al. BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. , 2009, Molecular cell.
[529] V. M. Sung,et al. Mechanistic overview of ADP-ribosylation reactions. , 2015, Biochimie.
[530] C. June,et al. Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies , 2015, Immunological reviews.
[531] J. Mestres,et al. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors , 2014, Oncotarget.
[532] J. Friedberg,et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. , 2014, The Lancet. Oncology.
[533] P. Loke,et al. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[534] J. Anastasi,et al. Diffuse large B-cell lymphoma--more than a diffuse collection of large B cells: an entity in search of a meaningful classification. , 2009, Archives of pathology & laboratory medicine.
[535] S. Levy,et al. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. , 1992, Journal of immunology.
[536] E. Campo,et al. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. , 2011, Blood.
[537] J. Vose,et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[538] L. Staudt,et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[539] R. Dalla‐Favera,et al. Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma , 2009, Nature.
[540] L. Staudt,et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma , 2009, Proceedings of the National Academy of Sciences.
[541] B. Teicher,et al. Antibody Conjugate Therapeutics: Challenges and Potential , 2011, Clinical Cancer Research.
[542] N. Gebauer,et al. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations , 2015, Leukemia & lymphoma.
[543] L. Medeiros,et al. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.
[544] M. Baccarani,et al. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study , 2013, Hematological oncology.
[545] Michael R. Green,et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. , 2012, Cancer cell.
[546] G. Lenz,et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma , 2013, Leukemia.
[547] Andreas Marg,et al. DNA binding controls inactivation and nuclear accumulation of the transcription factor Stat1. , 2003, Genes & development.
[548] A. Wiestner,et al. B-cell receptor signaling as a driver of lymphoma development and evolution. , 2013, Seminars in cancer biology.
[549] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[550] Matija Snuderl,et al. B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.
[551] R. Orlowski. Novel agents for multiple myeloma to overcome resistance in phase III clinical trials. , 2013, Seminars in oncology.
[552] S. Swerdlow. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .
[553] T. Clozel,et al. Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. , 2013, Cancer discovery.
[554] Jun Li,et al. STAT3 activation in monocytes accelerates liver cancer progression , 2011, BMC Cancer.
[555] G. Marti,et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. , 1983, Journal of immunology.
[556] Stefano Monti,et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.
[557] V. Landré,et al. Screening for E3-Ubiquitin ligase inhibitors: challenges and opportunities , 2014, Oncotarget.
[558] F. Giles,et al. The PIM kinases in hematological cancers , 2012, Expert review of hematology.
[559] R. Johnstone,et al. New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.
[560] T. Molina,et al. Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study. , 2010, Blood.
[561] J. Weigelt,et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors , 2012, Nature Biotechnology.
[562] S. Grant,et al. In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells , 2014, Molecular Cancer Therapeutics.
[563] David Dunson,et al. Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[564] M. Wasik,et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1) , 2008, Proceedings of the National Academy of Sciences.
[565] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[566] M. Trotter,et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. , 2015, Blood.
[567] E. Haralambieva,et al. BAL1/ARTD9 represses the anti-proliferative and pro-apoptotic IFN&ggr;–STAT1–IRF1–p53 axis in diffuse large B-cell lymphoma , 2013, Journal of Cell Science.
[568] L. Staudt,et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.
[569] Govind Bhagat,et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.
[570] S. Cho,et al. Collaborator of Stat6 (CoaSt6)-associated Poly(ADP-ribose) Polymerase Activity Modulates Stat6-dependent Gene Transcription* , 2007, Journal of Biological Chemistry.
[571] E. Borden,et al. Combinations of DNA Methyltransferase and Histone Deacetylase Inhibitors Induce DNA Damage in Small Cell Lung Cancer Cells: Correlation of Resistance with IFN-Stimulated Gene Expression , 2010, Molecular Cancer Therapeutics.
[572] U. Vinkemeier,et al. A Single Residue Modulates Tyrosine Dephosphorylation, Oligomerization, and Nuclear Accumulation of Stat Transcription Factors* , 2004, Journal of Biological Chemistry.
[573] A. DeFranco,et al. Lipid rafts and B cell signaling. , 2007, Seminars in cell & developmental biology.
[574] D. Ruggero,et al. Protein and Nucleotide Biosynthesis Are Coupled by a Single Rate-Limiting Enzyme, PRPS2, to Drive Cancer , 2014, Cell.
[575] Sadik H. Kassim,et al. Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor , 2013 .
[576] T. Witzig,et al. A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling , 2013, PloS one.
[577] R. Advani,et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes , 2015, Leukemia.
[578] A. Dalgleish,et al. A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: differences in action in vivo and in vitro , 2010, Molecular Biology Reports.
[579] R. Gascoyne,et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure , 2009, Haematologica.
[580] Bernard Roizman,et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. , 2007, Cancer research.
[581] C. Burgaleta,et al. Dose‐adjusted EPOCH plus rituximab is an effective regimen in patients with poor‐prognostic untreated diffuse large B‐cell lymphoma: results from a prospective observational study , 2007, British journal of haematology.
[582] J. Darnell,et al. Distinct Transcriptional Activation Functions of STAT1α and STAT1β on DNA and Chromatin Templates* , 2003, Journal of Biological Chemistry.
[583] Francesco Novelli,et al. Ups and downs: the STAT1:STAT3 seesaw of Interferon and gp130 receptor signalling. , 2008, Seminars in cell & developmental biology.
[584] G. Cattoretti,et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. , 2007, Blood.
[585] Z. Eshhar,et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[586] H. Tagawa,et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. , 2005, Blood.
[587] A. Rosenwald,et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[588] M. Gupta,et al. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy , 2012, Leukemia.
[589] G. Lenz,et al. PI3K/AKT addiction in subsets of diffuse large B-cell lymphoma , 2013, Cell Cycle.
[590] J. Friedberg,et al. The Bruton tyrosine kinase (BTK) inhibitor PCI‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib , 2013, British journal of haematology.
[591] D. Levy,et al. Stat Protein Transactivation Domains Recruit p300/CBP through Widely Divergent Sequences* , 1999, The Journal of Biological Chemistry.
[592] W. Grody,et al. [Diffuse large B-cell lymphoma]. , 2006 .
[593] A. Merlo,et al. Deltex-1 Activates Mitotic Signaling and Proliferation and Increases the Clonogenic and Invasive Potential of U373 and LN18 Glioblastoma Cells and Correlates with Patient Survival , 2013, PloS one.
[594] I. Lossos,et al. PTP1B is a negative regulator of interleukin 4-induced STAT6 signaling. , 2008, Blood.
[595] I. Lossos,et al. Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation , 2013, British journal of haematology.
[596] M. Kalos,et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[597] N. Curtin. PARP inhibitors for anticancer therapy. , 2014, Biochemical Society transactions.
[598] S. Larson,et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.
[599] B. Bonavida,et al. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[600] Saul H. Rosenberg,et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo , 2010, Cancer Chemotherapy and Pharmacology.
[601] M. Bøgsted,et al. Cell of origin associated classification of B-cell malignancies by gene signatures of the normal B-cell hierarchy , 2014, Leukemia & lymphoma.
[602] A. Isaksson,et al. STAT1 signaling is associated with acquired crossresistance to doxorubicin and radiation in myeloma cell lines , 2007, International journal of cancer.
[603] Stefano Monti,et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma , 2006, The Journal of experimental medicine.
[604] A. Zelenetz,et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[605] J. Cortes,et al. Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia , 2013 .
[606] U. Vitolo,et al. Lenalidomide in Diffuse Large B-Cell Lymphomas , 2012, Advances in hematology.
[607] B. Bonavida. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. , 2014, Seminars in oncology.
[608] P. Hassa. The molecular "Jekyll and Hyde" duality of PARP1 in cell death and cell survival. , 2009, Frontiers in bioscience.
[609] M. Czuczman,et al. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. , 2009, Oncology.
[610] M. Ziepert,et al. Six versus eight cycles of biweekly CHOP-14 with or without R in elderly patients (pts) with aggressive CD20+ B-cell lymphomas: Seven-year FU of the RICOVER-60 trial of the DSHNHL. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[611] K. Possinger,et al. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. , 2013, Cancer Letters.
[612] B. Jenkins,et al. Acquiring signalling specificity from the cytokine receptor gp130. , 2004, Trends in genetics : TIG.
[613] C. Wolf‐peeters,et al. T cell/histiocyte-rich large B-cell lymphoma: an update on its biology and classification , 2011, Virchows Archiv.
[614] L. Staudt,et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .
[615] E. Suzuki,et al. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis , 2007, Oncogene.
[616] A. Stoffel,et al. The p73 locus is commonly deleted in non-Hodgkin's lymphomas. , 2004, Leukemia research.
[617] L. Ferrarini,et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. , 2013, The Journal of clinical investigation.
[618] P. Güntert,et al. Structural insight into the interaction of ADP‐ribose with the PARP WWE domains , 2012, FEBS letters.
[619] C. Glass,et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. , 1998, Science.
[620] D. Spierings,et al. Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis1 , 2007, The Journal of Immunology.
[621] James E. Bradner,et al. Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.
[622] R. Gascoyne,et al. Newly identified mechanisms in B-cell non-Hodgkin lymphomas uncovered by next-generation sequencing. , 2013, Seminars in hematology.
[623] T. Habermann,et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma , 2010, American journal of hematology.
[624] A. Tarakhovsky,et al. Essential role of Src-family protein tyrosine kinases in NF-κB activation during B cell development , 2003, Nature Immunology.
[625] O. Elemento,et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.
[626] R. Arbeit,et al. Suppression of Molecular Inflammatory Pathways by Toll-Like Receptor 7, 8, and 9 Antagonists in a Model of IL-23-Induced Skin Inflammation , 2013, PloS one.
[627] H. McLeod,et al. Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells , 2013, PeerJ.
[628] M. Fassan,et al. The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies , 2012, Laboratory Investigation.
[629] Derek W. Yecies,et al. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. , 2010, Blood.
[630] S. Janz,et al. NF-κB/STAT3/PI3K signaling crosstalk in iMycEμ B lymphoma , 2010, Molecular Cancer.
[631] Hemant Ishwaran,et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.
[632] H. Schüler,et al. Comparative structural analysis of the putative mono-ADP-ribosyltransferases of the ARTD/PARP family. , 2015, Current topics in microbiology and immunology.
[633] S. Ogawa,et al. Dual antitumor mechanisms of Notch signaling inhibitor in a T‐cell acute lymphoblastic leukemia xenograft model , 2009, Cancer science.
[634] L. Staudt,et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[635] S. Pileri,et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. , 2011, Clinical lymphoma, myeloma & leukemia.
[636] Michel Sadelain,et al. The promise and potential pitfalls of chimeric antigen receptors. , 2009, Current Opinion in Immunology.
[637] Michael L. Wang,et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial , 2013, Leukemia.
[638] Tim J. Wigle,et al. The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states , 2011, FEBS letters.
[639] J. Friedberg,et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. , 2010, Blood.
[640] Mats Nilsson,et al. DNA repair genes are selectively mutated in diffuse large B cell lymphomas , 2013, The Journal of experimental medicine.
[641] M. Bøgsted,et al. Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. , 2014, Experimental hematology.
[642] L. Staudt,et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. , 2004, Immunity.
[643] A. Goy,et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma , 2014, British journal of haematology.
[644] Kajia Cao,et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. , 2004, The American journal of pathology.
[645] T. Taniguchi,et al. IRF family of transcription factors as regulators of host defense. , 2001, Annual review of immunology.
[646] J. Shah,et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[647] K. Harada,et al. Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2 , 2013, British Journal of Cancer.
[648] M. Davids,et al. Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. , 2014, Future oncology.
[649] J. Darnell,et al. Distinct transcriptional activation functions of STAT1alpha and STAT1beta on DNA and chromatin templates. , 2003, The Journal of biological chemistry.
[650] M. Seto,et al. Gain‐of‐function mutations and copy number increases of Notch2 in diffuse large B‐cell lymphoma , 2009, Cancer science.
[651] A. Ciulli,et al. Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4 , 2015, ACS chemical biology.
[652] W. Chan,et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma , 2005, Modern Pathology.
[653] R. Lahesmaa,et al. PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. , 2009, Blood.
[654] David Cunningham,et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles , 2013, The Lancet.
[655] R. Chopra,et al. A First In Human Dose Escalation Study Of CC-122, A First-In-Class Pleiotropic Pathway Modulator™ (PPM) Compound In Subjects With Relapsed Or Refractory Solid Tumors, Multiple Myeloma and Non-Hodgkin’s Lymphoma , 2013 .
[656] E. Sausville,et al. Phospho-p70S6K/p85S6K and cdc2/cdk1 Are Novel Targets for Diffuse Large B-Cell Lymphoma Combination Therapy , 2009, Clinical Cancer Research.